To build a versatile machine learning algorithm, one needs to gather a large amount of data.The data has to describe as accurately as possible the wide spectrum of emotional responses to a stimulus. For this task we planned two different experiments, one focuses on stress specifically and the other focuses on affective responses.
Prof. Alon Chen holds a BSc in life sciences and an MBA from Ben-Gurion University of the Negev, as well as a PhD through the Weizmann Institute of Science. After performing his postdoctoral research at the Salk Institute for Biological Studies in San Diego, California, Prof. Chen was awarded an Alon Fellowship by the Israel Council for Higher Education (Israel’s highest award for returning scientists), not long after earning the title of professor.
Prof. Chen’s research focuses on the biological processes by which stress and anxiety develop in our bodies, as well as regulatory mechanisms in the brain. On his exploration for a basic understanding of how humans respond to stress, Prof. Chen and his colleagues have exposed genes, proteins and neural circuits which are all crucial for the stress response and management.
In 2013, Prof. Chen was appointed a director of the Max Planck Institute of Psychiatry, and Head of the joint lab for experimental neuropsychiatry and behavioral neurogenetics. Additionally, on December 1st 2019, Prof. Chen will take office as the next president of the Weizmann Institute of Science.
Prof. Halevy is a medical specialist in internal medicine, digestive tract diseases and healthcare administration. He is also a Clinical Professor of Medicine at the Hebrew University Medical School.
Prof. Halevy is a Director at Van Leer Ventures Jerusalem, as well as the Chairman at Shaare Zedek Medical Center. Prof. Halevy plays a key role in quality improvement programs and medical risk management in Israeli healthcare institutions, serving as the Chairman of the Medical Risk Management Forum in the Medical Risk Management.
Dr. Ofer Sharon is a physician (internist) and entrepreneur with extensive experience in both clinical and commercial product development for startups in health tech, biotech, and medical devices. Ofer’s previous companies developed products that utilized change detection algorithms to identify clinical deterioration and intervene early to improve clinical outcomes. In the years 2011-2016 Ofer served as the Chief Medical Officer for Merck Israel, in this capacity Ofer founded a big data research collaborations.
Ofer’s main fields of interest include development and implementation of change detection algorithms for medical use and the development of patient engagement strategies with focus on complex medical situations and chronic diseases. Ofer is a Major (res.) in the IDF and a medical company commander with specific expertise on disaster areas and hazardous materials. Dr. Sharon serves on the boards of several companies and mentors several healthcare startups in Israel.
Prof. Hiroyuki Suzuki holds a B.S., M.S., and Ph.D. degrees in Science from the University of Tokyo, Japan. In 2007, Prof. Suzuki moved to Advanced Telecommunications Research Institute International (ATR), Kyoto, as a Vice President, Director, and in 2010 he became the Senior Vice President, Director. He is now the Executive Vice President, Representative Director, Head of Strategic Management Unit and Business Development Office, of ATR, and is in charge of corporate management and planning, and business developments, of ATR and ATR Group.
Prof. Suzuki is also a strategic director and the leader of Innovation Hub Activity of Keihanna Research Complex Project of Japan Science and Technology Agency (JST), in which he is creating a global innovation ecosystem together with local governments, big companies, SMEs, startups, universities, research institutes, and local residents.
Prof. Suzuki has published more than 300 scientific papers in international scientific journals and books, and holds more than 60 patents.